Evidence map›Paper›PMID 33180117›Full record

ArticleInvestigative ophthalmology & visual science2020

Innate Immune Interference Attenuates Inflammation In Bacillus Endophthalmitis.

Md Huzzatul Mursalin, Phillip S Coburn, Frederick C Miller, Erin T Livingston, Roger Astley, Michelle C Callegan

Open access · goldAbstract read
In one paragraph

Article in Investigative ophthalmology & visual science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. TheMicrobiology (Reading, England) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Md Huzzatul MursalinDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Phillip S CoburnDepartment of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States.
Frederick C MillerDepartment of Cell Biology and Department of Family and Preventive Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Erin T LivingstonDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Roger AstleyDepartment of Ophthalmology, Dean McGee Eye Institute, Oklahoma City, Oklahoma, United States.
Michelle C CalleganDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
Dean McGee Eye Institute · USUniversity of Oklahoma Health Sciences Center · US

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Wade Williams · 2018 to 2026
$27.1M
P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan, MICHAEL H ELLIOTT · 2011 to 2026
$10.5M
Pathogenic Mechanisms of Bacillus EndophthalmitisR01EY028810 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2018 to 2022
$1.8M
Vascular Permeability and Ocular InfectionsR01EY024140 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2014 to 2017
$1.6M
Nanotherapeutics for Ocular InfectionsR01EY025947 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C, ZHANG, LIANGFANG · 2015 to 2017
$1.1M
Targeting Chemokines in Intraocular InfectionR21EY028066 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI CALLEGAN, MICHELLE C · 2019 to 2020
$399k
NCI NIH HHS P30 CA225520NEI NIH HHS P30 EY021725NEI NIH HHS R01 EY024140NEI NIH HHS R01 EY025947NEI NIH HHS R01 EY028810NEI NIH HHS R21 EY028066
6 · The paper itself

Abstract

Purpose: To explore the consequences of innate interference on intraocular inflammatory responses during Bacillus endophthalmitis. Methods: Bacillus endophthalmitis was induced in mice. Innate immune pathway activation was interfered by injecting S layer protein-deficient (∆slpA) B. thuringiensis or by treating wild-type (WT)-infected mice with a TLR2/4 inhibitor (WT+OxPAPC). At 10 hours postinfection, eyes were harvested and RNA was purified. A NanoString murine inflammation panel was used to compare gene expression in WT-infected, WT+OxPAPC, ∆slpA-infected, and uninfected eyes. Results: In WT-infected eyes, 56% of genes were significantly upregulated compared to uninfected controls. Compared to WT-infected eyes, the expression of 27% and 50% of genes were significantly reduced in WT+OxPAPC and ∆slpA-infected eyes, respectively. Expression of 61 genes that were upregulated in WT-infected eyes was decreased in WT+OxPAPC and ∆slpA-infected eyes. Innate interference resulted in blunted expression of complement factors (C3, Cfb, and C6) and several innate pathway genes (TLRs 2, 4, 6, and 8, MyD88, Nod2, Nlrp3, NF-κB, STAT3, RelA, RelB, and Ptgs2). Innate interference also reduced the expression of several inflammatory cytokines (CSF2, CSF3, IL-6, IL-1β, IL-1α, TNFα, IL-23α, TGFβ1, and IL-12β) and chemokines (CCL2, CCL3, and CXCLs 1, 2, 3, 5, 9, and 10). All of the aforementioned genes were significantly upregulated in WT-infected eyes. Conclusions: These results suggest that interfering with innate activation significantly reduced the intraocular inflammatory response in Bacillus endophthalmitis. This positive clinical outcome could be a strategy for anti-inflammatory therapy of an infection typically refractory to corticosteroid treatment.

Indexed as

AnimalsBacillus thuringiensisChemokinesCytokinesDisease Models, AnimalEndophthalmitisEye Infections, BacterialGram-Positive Bacterial InfectionsImmunity, InnateInflammationMiceMice, Inbred C57BLNeutrophilsNF-kappa BPhosphatidylcholinesToll-Like Receptor 2ChemokinesCytokinesNF-kappa Boxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholinePhosphatidylcholinesTlr2 protein, mouseTlr4 protein, mouseToll-Like Receptor 2Toll-Like Receptor 4

Identifiers

PMID33180117
PMCPMC7671874
OpenAlexW3104156174

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.